You are here: Industry Insights > CoviDTH

News List

BioVaxys Begins Toxicity Study Ahead of CoviDTH IND Submission prnasia
October 13, 2021
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that it has started its planned in vivo animal toxicology study of CoviDTH in parallel with the preparation of an IND submission.
BioVaxys Bioproduction Partner WuXi Biologics Completes Synthesis Of Recombinant SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH Programs prnasia
September 23, 2021
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys"), announced today that global CDMO partner WuXi Biologics, has completed the synthesis of recombinant SARS-CoV-2 s-protein for BVX-0320...
Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans prnasia
August 04, 2021
BioVaxys Technology Corp. is pleased to announce that Immunologist Yvelise Barrios, MD, PhD, a specialist in Clinical Immunology at Hospital Universitario de Canarias, Tenerife, Spain, has joined BioVaxys as a Scientific Adviser to support development ...
FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical Trials Of CoviDTH prnasia
July 23, 2021
BioVaxys is pleased to announce that the US Food and Drug Administration has provided its official Written Response to the Company's request for a Pre-IND Type B review of CoviDTH as a diagnostic for evaluating T-cell immune response to SARS-CoV-2.
BioVaxys Receives Positive FDA Response For Pre-IND Review For CoviDTH Clinical Development prnewswire
June 15, 2021
BioVaxys Technology Corp. is pleased to announce today that FDA has reviewed its Pre-IND request for a Type B review of its CoviDTH program and has determined that a Written Response is sufficient to address the Company's questions regarding
BioVaxys Announces Appointment of Policy Advisor prnasia
May 21, 2021
BioVaxys Technology Corp., a biotechnology company that is advancing viral and oncology vaccine platforms as well as immuno-diagnostic products, announced the appointment of Adam Coutts, PhD, as Policy Advisor.